Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386171 | 1.00 | FFAR1 (0.80) | FFAR1GNA15 | |
| SCHEMBL3983585 | 0.90 | FFAR1 (0.82) | FFAR1GNA15 | |
| SCHEMBL15199299 | 0.89 | FFAR1 (0.72) | FFAR1GNA15 | |
| SCHEMBL13118104 | 0.89 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL13118103 | 0.89 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL13118011 | 0.89 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL30618896 | 0.85 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL3519304 | 0.85 | FFAR1 (0.93) | FFAR1GNA15 | |
| SCHEMBL435029 | 0.85 | FFAR1 (0.59) | FFAR1GNA15 | |
| SCHEMBL435028 | 0.85 | FFAR1 (0.59) | FFAR1GNA15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2963027-B1 | TRICYCLIC COMPOUND AND USE THEREOF | TIUMBIO CO LTD (KR) | 2018-12-26 | — | — | EP | disclosed |
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| EP-2822950-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| EP-2963027-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK Chemicals Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
| US-9006235-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130237499-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | FFAR1 24/4885GNA15 596/4885 |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | FFAR1 22/4885GNA15 631/4885 |
| US-20130237499-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | FFAR1 4461/4885GNA15 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.